Get the latest tech news
HIV drug could be made for just $40 a year for every patient
Generic version of a drug already on the market, which can suppress and prevent HIV, would still yield 30% profit if the current price was slashed, researchers say
In a study presented at the 25th international Aids conference in Munich onTuesday, experts calculated that the minimum price for mass production of a generic version, based on the costs of lenacapavir’s ingredients and manufacturing, and allowing for 30% profit, was $40 a year , assuming 10 million people used it annually. Ouma said: “It’s not an exaggeration to say that meeting the 2030 goal of ending new HIV transmissions hinges on Gilead ensuring people in the global south have fair access to lenacapavir.” Winnie Byanyima, executive director of UNAids, said treatment could be “life-saving” by providing a more discreet option than daily tablets for people who faced stigma because of their HIV status or sexuality.
Or read this on Hacker News
